Sibutramine

Sibutramine is an anti-obesity drug, Sibutramine is structurally related to amphetamine. Sibutramine is a serotonin and noradrenaline reuptake inhibitor. It should be avoided in anorexia nervosa or in poorly controlled or uncontrolled hypertension.

Sibutramine is primarily indicated in conditions like Bleeding caused by uterine atony, Obesity.

Sibutramine is contraindicated in conditions like Hyperthyroidism, Pheochromocytoma, Prostatic hypertrophy, Congestive heart failure, Cerebrovascular disease, Coronary artery disease, Angle-closure glaucoma, Uncontrolled hypertension, Peripheral arterial occlusive disease, Psychotic illness, Thyrotoxicosis (adjunct), Infections due to sensitive gram +ive and gram -ive bacteria.

The severe or irreversible adverse effects of Sibutramine, which give rise to further complications include Increased blood pressure, Seizures, Bleeding, Acute interstitial nephritis, Migraine. The symptomatic adverse reactions produced by Sibutramine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Diarrhea, Constipation, Insomnia, Dry mouth, Depression, Edema, Rhinitis, Dysmenorrhea.

Monitor blood pressure and pulse rate (every two weeks for first three months then monthly for three months then at least every three months)-discontinue if blood pressure exceeds 145/90 mmHg or if systolic or diastolic pressure raised by 10mmHg or if pulse rate raised by 10 beats per minute at two consecutive visits; sleep apnea syndrome (increased risk of hypertension); epilepsy; hepatic impairment (avoid if severe); renal impairment (avoid if severe); monitor for pulmonary hypertension; family history of motor or vocal tics. DISCONTINUATION OF TREATMENT: Discontinue treatment if : weight loss after three months less than 5% of initial body weight; weight loss stabilizes at less than 5% of initial body weight; individuals regain 3 kg or more after previous weight loss. In individuals with co-morbid conditions, treatment should be continued only if weight loss is associated with other clinical benefits.

Drug should not be given to Cardiac / Hypertensive Patients. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

10 mg (10 (10)) 24 hourly PO — Initially, increased to 15mg if weight loss is

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Sibutramine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementDextromethorphanEphedrineErythromycinFentanyl (Citrate)KetoconazoleLithiumPentazocinePethidine (HCl)Phenylpropanolamine (HCl)Pseudoephedrine (HCl)SumatriptanVORICONAZOLEVoriconazole may increase the serum concentration of sibutramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Caps Store in a well closed container, Between 15°C-30°C. Protect from Sunlight, Moisture and Heat.